-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Company Establishment Time
Stock Code
Professional and technical personnel
Products are available nationwide
Service Platform
Active Pharmaceutical Ingredient (API) CMO/CDMO Business Formulated Pharmaceutical Products (CMO/CDMO Business) Medical Aesthetic Materials (CMO/CDMO Business) Specialized Pilot Production Platform
Technology Platform
Nitrification technology Hydrogenation technology Sulfonation technology Fluorination technology Chiral catalysis technology Enzyme catalysis technology
Shandong Keyuan Pharmaceutical Co.,Ltd.
Shandong Keyuan Pharmaceutical Co.,Ltd. is a domestic enterprise in the chemical raw material medicine segment, with products covering key disease areas such as hypoglycemic, anesthetic, cardiovascular and mental diseases.
The company focuses on the research, development, production and sales of chemical raw materials and their preparations. Core products have successively passed official drug administration certifications from multiple countries, including EU CEP, US FDA, Japan PMDA, and Korea MFDS.
After successfully listing on April 4, 2023, Keyuan Pharmaceutical has entered a stage of rapid development driven by both digital intelligence and capital, with business covering dozens of countries and regions around the world.
Corporate Honors
With its cutting-edge technological innovation, technological research and development capabilities, and hard-core quality control capabilities, Keyuan Pharmaceutical has won numerous awards.
High-tech enterprise
Jinan Green Factory
Top 50 Sci-Tech Innovative Private Enterprises in Jinan
Jinan City New and Old Kinetic Energy Conversion Public Training Base
Product Center
The company has been deeply engaged in chemical raw materials for more than 20 years, continuously strengthening its core advantages in the fields of hypoglycemic and cardiovascular diseases, actively expanding new business areas such as cosmetic raw materials, high-end pharmaceutical excipients, and functional food additives, and building an industrial ecosystem of "raw materials + multi-field synergy".
Beijing R&D Base: Nuokangda
Beijing Nuokanda Pharmaceutical Technology Co., Ltd. is an innovation-driven, full-chain pharmaceutical CRO enterprise specializing in formulation technology platforms tailored to clinical needs. It is recognized as a National High-Tech Enterprise, a National Intellectual Property Demonstration Enterprise, and hosts a Postdoctoral Research Station. For six consecutive years, the company has been ranked among the top 20 "China's Top 20 Pharmaceutical R&D Companies" by the All-China Federation of Industry and Commerce, and it has undertaken or participated in two key national major new drug development projects under the 13th Five-Year Plan. In 2023, Keyuan Pharmaceutical acquired a 12% stake in Nuokanda, making it the company's second-largest shareholder. Today, Nuokanda has become Keyuan Pharmaceutical's Beijing-based R&D hub.
Focus on Keyuan Dynamics
Listen to Keyuan's voice, perceive the pulse of innovation, focus on the forefront of the industry, and work together to create a new chapter of development
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating intelligent manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed strong recognition of its practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
2026-05-17
On May 13, the 92nd National Pharmaceutical Fair and the 94th China International API, Intermediates, Packaging, and Equipment Fair (API China) opened simultaneously at the Shanghai National Exhibition and Convention Center. As an innovative, publicly listed company in China’s chemical pharmaceutical sector, Shandong Keyuan Pharmaceutical Co., Ltd. (301281.SZ), together with its wholly owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd., made a high‑profile appearance, showcasing synergistic raw material–formulation integration, end-to-end product displays, and brand resonance. The company highlighted its robust capabilities in innovative R&D, digital and intelligent manufacturing, green production, global supply chains, and clinical translation, while engaging domestic and international partners to explore new industry trends, expand avenues for collaboration, and build a new ecosystem for the pharmaceutical and healthcare sectors.
2026-05-13
Contact Keyuan
For any questions or cooperation intentions, please feel free to contact us.
Our team is always ready to provide you with professional support and solutions!
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline